Clinical Trials Directory

Trials / Completed

CompletedNCT05236335

Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Cardiovascular Effects.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
24 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial hemodynamics effect in patients with hearth failure with reduced ejection fraction. However, this have never been investigated in patients with heart failure with preserved ejection fraction (HFpEF). In this study we would like to investigate the effect of 14 days modulation of circulating ketone body levels on cardiac function and exercise capacity in patients with HFpEF and T2D.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTKetone esterCommercially available ketone supplement
DIETARY_SUPPLEMENTPlacebo drinkIsocaloric placebo

Timeline

Start date
2022-02-01
Primary completion
2023-06-15
Completion
2023-06-15
First posted
2022-02-11
Last updated
2023-10-10

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05236335. Inclusion in this directory is not an endorsement.